Carbidopa with levodopa extended release is indicated for the treatment of Parkinson’s disease and syndrome.
These generic extended release versions of carbidopa with levodopa are bio-equivalent to Sinemet CR marketed by Bristol-Myers and Squibb Company and will be available as tablets in two strengths: 25mg carbidopa with 100mg levodopa and 50mg carbidopa with 200mg levodopa. The company expects to reach the market shortly with these products.